Publications Office of the EU
Health products for drug supply for the years 2025-2028 (37 months), as of 01 04 2025 GCS ASO - EU tenders
DisplayCustomHeader
MyPortal
Language Selector
English
BasketSummary
Procurement Detail Actions Portlet

Utilities

Procurement Detail Actions Portlet
OP Portal - Procurement - Details

This page contains content generated automatically to improve findability and accessibility

- indicates CPV codes deduced from the text of the procedure

- indicates text translated automatically in your browsing language

Health products for drug supply for the years 2025-2028 (37 months), as of 01 04 2025 GCS ASO Text automatically translated in your browsing language Automatically translated

Overview
  • Published
    27/08/2024
  • Deadline
    23/10/2024
  • Today
    22/04/2025
Status
Submission closed
Type of contract
Supplies
Subject for Renewal
No
Buyer
GCS Achats Santé en Occitanie
Place of performance
NUTS code: Multiple place of performance
Location of buyer
NUTS code: Not available
Business sector (Main CPV)
33600000 Pharmaceutical products
Total estimated contract value (excluding VAT)
Not available
Total final contract value (excluding VAT)
Not available
Procedure details
Tender reference number
AO 2025 MEDI5 GCS ASO
Description

Framework agreement of the Occitanie GCS ASO Health Purchasing Cooperation Group for supplies of pharmaceutical products: medicines for ATC families: A, B, C, G, H, L, N, R, S pour 31 lots - metopimazine 7,5 mg orod, selenium 100 µg inj, laxatifs constipation antagonistes des recepteurs opioïdes peripheriques, gliclazide 60 mg lm oral, albumine 20% 100 ml inj, dabigatran oral, fer 100 mg inj, fer inj, rivaroxaban oral, mélange de nutrition ternaire veine centrale avec electrolytes, labetalol inj, cyproterone acetate 50 mg oral, lanreotide lp inj, octreotide lp inj, methotrexate 2,5 mg oral, tamoxifene 20 mg oral, azacitidine inj, eribuline inj, plerixafor inj, vinorelbine 50 mg inj, natalizumab 150 mg sc, natalizumab 300 mg inj, pomalidomide oral, tocilizumab 162 mg sc inj, tocilizumab inj, zonisamide oral, milnacipran oral, venlafaxine 150 mg lp oral, omalizumab inj, antiglaucomateux prostaglandine + timolol 0.5 collyre unidoses, ranibizumab intravitreen inj Text automatically translated in your browsing language Automatically translated

Submission Method
Electronic via:
https://www.achatpublic.com/sdm/ent2/gen/ficheCsl.action?PCSLID=CSL_2024_nlDnpj7vCb
Tenders may be submitted
Electronic submission: required
https://www.achatpublic.com/sdm/ent2/gen/ficheCsl.action?PCSLID=CSL_2024_nlDnpj7vCb
Information about a public contract, a framework agreement or a dynamic purchasing system (DPS)
The procurement involves the establishment of a framework agreement
Conditions for opening tenders (date)
Not available
Place of performance
FR France
Any country
CPV code

33600000 - Pharmaceutical products

33660000 - Medicinal products for the nervous system and sensory organs CVP code deduced from the text of the procedure AI-generated

Award method
Not available
Estimated value
Not available
Final contracted value
Not available
Award of contract
Not available
Documents
Prior information
Contract
Award
Footnote - legal notice

This content published on this page is meant purely as an additional service and has no legal effect. The Union's institutions do not assume any liability for its contents. The official versions of the relevant tendering notices are those published in the Supplement of Official Journal of the European Union and available in TED. Those official texts are directly accessible through the links embedded in this page. For more information please see Public Procurement Explainability and Liability notice.